The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

Background: Multiple myeloma (MM) is the second most common hematological malignancy that still lacks effective clinical treatments. In particular, MM with central nervous system (CNS) invasion occurs ...

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 ...

Introduction Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic malignancies. The overall prognosis is driven by tumor biology but other ...

Multiple myeloma (MM) is a form of blood cancer that originates from plasma cells – part of the white blood cell produced by the bone marrow responsible for providing the human body with the ...